Oral antifungal therapy for chronic rhinosinusitis and its subtypes: a systematic review

2011 ◽  
Vol 1 (5) ◽  
pp. 382-389 ◽  
Author(s):  
Thunchai Thanasumpun ◽  
Pete S. Batra
Keyword(s):  
Systematic Review ◽  
Chronic Rhinosinusitis ◽  
Antifungal Therapy

Endoscopic Sinus Surgery Improves Sleep Quality in Chronic Rhinosinusitis: A Systematic Review and Meta-analysis

2017 ◽  
Vol 158 (2) ◽  
pp. 249-256 ◽  
Author(s):  
Daniel C. Sukato ◽  
Jason M. Abramowitz ◽  
Marina Boruk ◽  
Nira A. Goldstein ◽  
Richard M. Rosenfeld
Keyword(s):  
Systematic Review ◽  
Sleep Quality ◽  
Chronic Rhinosinusitis ◽  
Endoscopic Sinus Surgery ◽  
Meta Analysis ◽  
Research Direction ◽  
Sinus Surgery ◽  
Future Research ◽  
Apnea Hypopnea Index ◽  
Poor Sleep

Objective Up to 75% of patients with chronic rhinosinusitis (CRS) suffer with poor sleep quality and reduced quality of life. Endoscopic sinus surgery has demonstrated encouraging results in improving sleep function. The aim of this systematic review is to assess the change in sleep quality after surgery for CRS. Data Sources PubMed, Web of Science, EMBASE. Review Methods An electronic search was conducted with the keywords “sinusitis” or “rhinosinusitis” and “sleep.” Studies were included only when adults underwent endoscopic sinus surgery and were evaluated pre- and postoperatively by the Epworth Sleepiness Scale (ESS), the Pittsburgh Sleep Quality Index (PSQI), the Apnea-Hypopnea Index (AHI), the sleep domain of Sino-Nasal Outcome Test–22, or the sleep domain of Rhinosinusitis Disability Index. Results The database search yielded 1939 studies, of which 7 remained after dual-investigator screening. The standardized mean differences (95% CI) for the ESS, PSQI, and AHI were −0.94 (−1.63 to −0.26), −0.80 (−1.46 to −0.14), and −0.20 (−0.32 to −0.07), indicating large, moderate to large, and small improvements, respectively. All analyses displayed high heterogeneity ( I2 = 95%-99%). Conclusion Sleep quality, as measured by the ESS and PSQI surveys, shows substantial improvement after surgery for CRS, with smaller improvement seen for AHI. Generalizability of our results is limited by high heterogeneity among studies and by broad confidence intervals that cannot exclude small to trivial changes. The findings of this meta-analysis provide insight into the effect of CRS-related endoscopic sinus surgery on sleep quality, which should guide future research direction and counseling of patients in the clinical setting.

Surgical therapy vs continued medical therapy for medically refractory chronic rhinosinusitis: a systematic review and meta-analysis

2016 ◽  
Vol 7 (2) ◽  
pp. 119-127 ◽  
Author(s):  
Zara M. Patel ◽  
Andrew Thamboo ◽  
Luke Rudmik ◽  
Jayakar V. Nayak ◽  
Timothy L. Smith ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Rhinosinusitis ◽  
Medical Therapy ◽  
Surgical Therapy ◽  
Meta Analysis

scholarly journals Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials

BMJ Open ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. e047344
Author(s):  
Qingwu Wu ◽  
Lianxiong Yuan ◽  
Huijun Qiu ◽  
Xinyue Wang ◽  
Xuekun Huang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Adverse Events ◽  
Chronic Rhinosinusitis ◽  
Randomised Controlled Trials ◽  
Nasal Polyps ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Randomised Controlled

ObjectivesTo assess the efficacy and safety of omalizumab for chronic rhinosinusitis with nasal polyps (CRSwNP) and to identify evidence gaps that will guide future research on omalizumab for CRSwNP.DesignSystematic review and meta-analysis.Data sourcesA comprehensive search was performed in PubMed, Embase, Web of Science and the Cochrane Library on 13 October 2020.Eligibility criteriaRandomised controlled trials (RCTs) comparing omalizumab with placebo, given for at least 16 weeks in adult patients with CRSwNP.Data extraction and synthesisTwo independent authors screened search results, extracted data and assessed studies using the Cochrane risk of bias tool. Data were pooled using the inverse-variance method and expressed as mean differences (MDs) with 95% CIs. Heterogeneity was assessed by the χ2 test and the I2 statistic.ResultsA total of four RCTs involving 303 participants were identified. When comparing omalizumab to placebo, there was a significant difference in Nasal Polyps Score (MD=−1.20; 95% CI −1.48 to −0.92), Nasal Congestion Score (MD=−0.67; 95% CI −0.86 to −0.48), Sino-Nasal Outcome Test-22 (MD=−15.62; 95% CI −19.79 to −11.45), Total Nasal Symptom Score (MD=−1.84; 95% CI −2.43 to −1.25) and reduced need for surgery (risk ratio (RR)=5.61; 95% CI 1.99 to 15.81). Furthermore, there was no difference in the risk of serious adverse events ((RR=1.40; 95% CI 0.29 to 6.80), adverse events (RR=0.83; 95% CI 0.60 to 1.15) and rescue systemic corticosteroid (RR=0.52; 95% CI 0.17 to 1.61).ConclusionsThis was the first meta-analysis that identified omalizumab significantly improved endoscopic, clinical and patient-reported outcomes in adults with moderate to severe CRSwNP and it was safe and well tolerated.PROSPERO registration numberCRD42020207639.

High tissue eosinophilia as a marker to predict recurrence for eosinophilic chronic rhinosinusitis: a systematic review and meta-analysis

2018 ◽  
Vol 8 (12) ◽  
pp. 1421-1429 ◽  
Author(s):  
Tobial McHugh ◽  
Kornkiat Snidvongs ◽  
Michael Xie ◽  
Sarfaraz Banglawala ◽  
Doron Sommer
Keyword(s):  
Systematic Review ◽  
Chronic Rhinosinusitis ◽  
Meta Analysis ◽  
Tissue Eosinophilia ◽  
Eosinophilic Chronic Rhinosinusitis

Comorbidities associated with eosinophilic chronic rhinosinusitis: A systematic review and meta‐analysis

2020 ◽  
Vol 45 (4) ◽  
pp. 574-583
Author(s):  
Tobial McHugh ◽  
Marc Levin ◽  
Kornkiat Snidvongs ◽  
Sarfaraz M. Banglawala ◽  
Doron D. Sommer
Keyword(s):  
Systematic Review ◽  
Chronic Rhinosinusitis ◽  
Meta Analysis ◽  
Eosinophilic Chronic Rhinosinusitis

scholarly journals Antifungal therapy for chronic rhinosinusitis: the controversy persists

2009 ◽  
Vol 9 (1) ◽  
pp. 67-72 ◽  
Author(s):  
Matthew A Rank ◽  
Cheryl R Adolphson ◽  
Hirohito Kita
Keyword(s):  
Chronic Rhinosinusitis ◽  
Antifungal Therapy

scholarly journals Definition and characteristics of acute exacerbation in adult patients with chronic rhinosinusitis: a systematic review

2020 ◽  
Vol 49 (1) ◽  
Author(s):  
Dawei Wu ◽  
Benjamin Bleier ◽  
Yongxiang Wei
Keyword(s):  
Systematic Review ◽  
Chronic Rhinosinusitis ◽  
Case Reports ◽  
Percentage Increase ◽  
Clinical Issue ◽  
Patient Reported ◽  
Acute Exacerbations ◽  
Quantitative Changes ◽  
Definition Of ◽  
Snot 22

Abstract Background Acute exacerbations (AE) in chronic rhinosinusitis (CRS) have been increasingly recognized as an important clinical issue. The purpose of this study is to summarize the current definitions and evaluation parameters of AE and then identify and quantify the clinical and immunopathologic characteristics of AE in CRS. Methods A systematic review of the literature was performed on PubMed, Scopus, and Cochrane databases from January 1990 through August 2020 to identify studies relating to AE in CRS. Exclusion criteria included non-English and non-human studies, and case reports. Results The definitions of AE in CRS among all the studies were based on a description of short-term worsening sinonasal symptoms. Patient-reported sinus infection and exacerbation related medical treatment during the preceding 3 months to 1 year were used to evaluate the frequency of AE in CRS. The average decline in 22-item Sino-Nasal Outcome Test (SNOT-22) score during an exacerbation was 7.83 points relative to baseline. Comorbid asthma, SNOT-22 scores ≥24, allergic rhinitis, eosinophil count ≥150/μL and autoimmune disease were positively associated with an exacerbation-prone CRS phenotype. AE in chronic rhinosinusitis with nasal polyps (CRSwNP) was associated with increased expression of mucus cytokines including myeloperoxidase (percentage increase [PI] = 101%), IL-5 (PI = 125%), and IL-6 (PI = 162%) and could be predicted by the increasing mucus cystatin and periostin. Conclusion The definition of AE in CRS is largely driven by patient-reported symptoms and is associated with several risk factors. Quantitative changes in mucus cytokines associated with AE in CRSwNP and may be used to predict events. The development of a consistent definition of AE in CRS is critical to help define disease control and treatment efficacy.

Sign in / Sign up

Export Citation Format

Share Document